BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:HRS-5346 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of HRS-5346\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07767513-1081@assetmemo.bio
DTSTAMP:20261121T010123Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:HRS-5346: Phase 2 readout est. (NCT07767513)
DESCRIPTION:HRS-5346\, phase 2\, Atherosclerotic Cardiovascular Disease.\nS
 tudy: Study of Oral HRS-5346 in Adult Patients With Elevated Lipoprotein(a
 ) and High Risk of Cardiovascular Events\nEstimated primary completion: Fe
 bruary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/hrs-5346
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT077
 67513
URL:https://assetmemo.bio/drug/hrs-5346#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07614984-1081@assetmemo.bio
DTSTAMP:20261121T010123Z
DTSTART;VALUE=DATE:20271012
DTEND;VALUE=DATE:20271013
SUMMARY:HRS-5346: Phase 2 readout est. (NCT07614984)
DESCRIPTION:HRS-5346\, phase 2\, Atherosclerotic Cardiovascular Disease.\nS
 tudy: A Clinical Trial of MK-7262 and Enlicitide in Participants With High
  Lipoprotein(a) (MK-7262-004)\nEstimated primary completion: 12 October 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/hrs-5346#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07614984
URL:https://assetmemo.bio/drug/hrs-5346#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
